Contract development injectable company Grand River Aseptic Manufacturing (GRAM) announced on Friday that it has signed an agreement to support the manufacture of Johnson & Johnson's Janssen Pharmaceuticals Inc SARS-CoV-2 vaccine candidate.
This agreement includes the technical transfer and fill and finish manufacture of Johnson & Johnson's SARS-CoV-2 vaccine candidate to GRAM's new, state-of-the-art facility and now swiftly preparing for the start of vaccine production.
The Johnson & Johnson vaccine candidate being manufactured at GRAM is being developed, in part, with funding from BARDA. BARDA, in collaboration with JPEO-CBRND, is funding a demonstration of manufacturing capability that is expected to result in 100m doses of the investigational vaccine which the federal government will own.
Through advanced aseptic fill and finish services, GRAM's Johnson & Johnson's COVID-19 vaccine candidate would be available upon regulatory approval. GRAM will utilize its world-class 60,000 sq. ft. large-scale fill and finish facility located in Grand Rapids, MI.
Virbac expands presence in Japan with Sasaeah acquisition
Pfizer reveals strong efficacy data for ABRYSVO in older adults against RSV
US CDC advisory committee backs Valneva's chikungunya vaccine
Takeda and Biological E. Limited join forces to combat global dengue threat
SK bioscience 'SKYTyphoid' receives WHO prequalification certification
ImmunityBio advances cancer vaccine trial for Lynch syndrome participants
AstraZeneca boosts vaccine portfolio with acquisition of Icosavax
Ultimovacs gains EMA Orphan Drug status for UV1 cancer vaccine in mesothelioma